SVRA

Savara (SVRA)

About Savara (SVRA)

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Details

Daily high

$4.38

Daily low

$4.21

Price at open

$4.32

52 Week High

$4.50

52 Week Low

$1.89

Market cap

845.6M

Dividend yield

0.00%

Volume

1.3M

Avg. volume

1.7M

P/E ratio

-8.04

Savara News